Peter Mac today installed the first model of an Australian-designed 3D bio-printer, which promises to dramatically accelerate research into potential new cancer drugs.
Peter MacCallum Cancer Centre welcomes the Therapeutic Goods Administration (TGA) announcement that Novartis Kymriah® (tisagenlecleucel, formerly CTL019) has been approved for treating two aggressive blood cancers.
Professors John Seymour, Mark Dawson and Sarah-Jane Dawson, and Dr Piers Blombery, spoke as presenting authors at the ASH annual scientific meeting in San Diego recently. Attendees learned the latest about their discoveries and successful clinical trials at Peter Mac. These presentations were among a total of 40 papers delivered with Haematology staff as contributing authors, including 16 oral presentations.
In a Victorian first, Peter Mac is expanding its services to patients at the Albury-Wodonga Regional Cancer Centre and Bendigo Health, with new initiatives combining world-class research and remote delivery of clinical trials.
Surgery is a central tenet of cancer care, with around 60% of cancer patients requiring this as part of their treatment. Peter Mac's Professor Bernhard Riedel will lead an international study that will determine if the type of anaesthetic used in cancer surgery affects patient recovery and survival rates.
Melbourne researchers have identified a gene mutation in the leukaemia cells of patients who become resistant to venetoclax, a discovery which can be used to identify those at-risk of relapse and help improve outcomes from this breakthrough blood cancer drug.
Researchers at Peter Mac have discovered a genetic mutation which may lead to a new combination drug treatment to be tested in forthcoming clinical trials in Mantle Cell Lymphoma (MCL) patients.
Peter Mac was delighted to host The Hon. Greg Hunt MP, Minister for Health, to announce important changes to the PBS which will provide or improve subsidised access to life-changing cancer drugs.